Correction to: Validation of the Spanish Version of Fear of COVID-19 Scale: its Association with Acute Stress and Coping

[This corrects the article DOI: 10.1007/s11469-021-00615-x.].

Validation of the Spanish Version of Fear of COVID-19 Scale: its Association with Acute Stress and Coping its Association with Acute Stress and Coping

The COVID-19 is a “unique” stressor, which can produce physical and psychological trauma. Coping styles can buffer this psychological impact. Consequently, this paper aims to psychometrically adapt the Fear of COVID-19 scale (FCV-19S) to Spanish and examines the relationships between FCV-19S, stress response, and coping strategies. The sample comprised a convenience sample of 1146 participants (12–83 years), 880 from Spain (76.8%), and 266 from Dominican Republic (23.2%). Overall, the findings support a one-factor structure for FCV-19S, consisting of 7-items, and was invariant across age, sex, occupational status, and cross-national. Therefore, indicating evidences of construct validity. Evidences of reliability were also observed (Cronbach’s α = .86, McDonald’s ω = .86, Guttmann’s λ6 = .86, greatest lower bound = .91, composite reliability = .85, and average variance extracted = .44). Moreover, as regards criterion-related validity, the mediation analysis indicated that the relationship between FCV-19S and acute stress was positive and high, with maladaptive coping styles mediating the relationship, and with a stronger mediation for men. The findings give evidences of the reliability and validity of the Spanish version of FCV-19S among Spanish-speaker participants, which provides the chance of cross-cultural studies.

Determining personalized treatment by gene expression profiling in metastatic breast carcinoma patients: a pilot study

PURPOSE

The present study evaluates the massive study of gene expression in metastatic breast carcinoma (MBC) patients using microarray gene expression profiling (MAGE) complemented with conventional sequencing, immunohistochemistry (IHC) and fluorescent "in situ" hybridization (FISH), seeking to optimize the treatment in a subset of heavily pretreated patients and with limited life expectancy.

PATIENTS, MATERIAL AND METHODS

MBC patients in hormone therapy progression with survival expectancy of at least 3 months (m) have been included. The MAGE contains gene probes representing genes known to potentially interact with available drugs as cited in the literature.

RESULTS

Thirty-nine procedures were performed from October 2010 to April 2016. Within the 30 evaluable procedures, considering all hormonal manipulations as a single line, the patients had received a median of 4 treatment lines prior to MAGE (range 1-7). Progression was observed in 6 cases, stable disease (SD) in 7 cases and partial response (PR) in 16 cases, which implies a clinical benefit rate (SD + PR) of 76%. Actuarial median progression-free survival (PFS) was 6 m (95% CI 2.5-9.5) in patients with clinical benefit. The median overall survival (OS) for the entire series was 11 m (95% CI 2.2-19.8).

CONCLUSION

Data presented here indicate that the use of MAGE provides relevant information to establish personalized treatment in frail patients with limited life expectancy in which therapeutic futility is a particularly difficult burden to assume.

[Stability study of oxaliplatin and doxorubicin for intraperitoneal administration with hyperthermia]

OBJECTIVE

To evaluate the in vitro physicochemical stability of oxaliplatin and doxorubicin when the in vivo hyperthermic intraperitoneal conditions are reproduced.

METHODS

Three solutions were prepared, A (oxaliplatin 200 mg/L), B(doxorubicin 15 mg/L) and C (oxaliplatin 200 mg/L with doxorubicin 15mg/L) in glucose 5%. The three solutions were subjected to the maximum temperature reached in vivo (49° C) for two hours. Physical stability was focused on visual control of particles or precipitates in solutions, discharge of gases, odor and color. Samples were taken every 15 minutes and the chemical stability was evaluated by determining the concentration of oxaliplatin and doxorubicin remaining in the samples. Oxaliplatin concentrations were determined by atomic absorption graphite chamber while doxorubicin was determined by high performance liquid chromatography.The chemical stability criteria selected was the one described by the American Pharmacopoeia, which sets a permissible variation range between the 90-110% of the initial concentration.

RESULTS

During the assay there was no appearance of particles, precipitates in the samples, discharge of gases, nor colour changes in the solutions. The samples showed a remaining concentration of oxaliplatin and doxorubicin within the 90-110% limit. The stability of the samples that follow to two cycles of freeze-thaw after hyperthermia was also found within the specified limits.

CONCLUSION

A, B and c solutions in 5% glucose, are physically and chemically stable at 49° C for two hours. Under these conditions, these solutions could be used with guarantees of stability in patients with peritoneal carcinomatosis subsidiary of intraperitoneal hyperthermic chemotherapy based in these antineoplastic agents.

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs)

INTRODUCTION Epidermal growth factor receptor (EGFR) mutation related to tyrosine kinase inhibitors' (TKIs) responsiveness in non-small cell lung cancer (NSCLC) has become an important issue for therapeutic decision-making in NSCLC patients. MATERIAL AND METHODS Sixty-nine Caucasian NSCLC patients were screened for mutations in the tyrosine kinase (TK) domain of EGFR by direct sequencing from December 2005 to September 2010. RESULTS Activating mutations in the EGFR TK domain were found in 8 of 69 (11.6%) (7 deletions in exon 19 and one L858R mutation in exon 21). Seven of those mutations were found in adenocarcinoma and one mutation in bronchiolo-alveolar carcinoma; five of them in females (one smoker) and three of them in males (one smoker). All patients carrying activating mutations in the TK domain of EGFR were treated with TKIs. Ten patients not carrying an activating mutation in EGFR, who progressed after chemotherapy, were also treated with compassionate use of EGFR-specific TKIs (gefitinib or erlotinib). An objective response (partial response) was observed in all patients carrying an activating mutation in EGFR that received TKIs. Median overall survival for these patients has not been reached, however mean survival has been estimated at 39.5 months (95% CI, 22-57). CONCLUSIONS As previously reported, EGFR TK mutational analysis was a predictive test for response to targeted therapy with EGFR TKIs. The early identification of these patients consistently attains disease response and clearly improves outcomes.

[Population pharmacokinetics of gemcitabine applied to personalize the dosage used in cancer patients]

OBJECTIVE

To develop and internally validate a population pharmacokinetic model for gemcitabine and its metabolite 2',2'-difluorodeoxyuridine (dFdU); and to evaluate its predictive perfomance for personalizing the dosage used in cancer patients.

METHODS

Gemcitabine and dFdU plasma concentrations were determined in 18 cancer patients. A 2-compartment pharmacokinetic model was implemented in the NONMEN VI program to determine the appropriate pharmacokinetic parameters. The power to identify the parameters was assessed by parametric bootstrap, and the internal model validation was performed using nonparametric bootstrap and visual and numerical predictive check methods. The final predictive performance of the model was assessed for accuracy and precision during the first (a priori) and second (a posteriori) chemotherapy cycles.

RESULTS

The mean and interpatient variability of gemcitabine and dFdU clearance was 2.70 L/min (31.0%) and 0.0515 L/min (35.8%), respectively. The estimated distribution volume at steady state was 30 L for gemcitabine and 238 L for dFdU. Internal validation confirmed that the population pharmacokinetic model was appropriate for describing the plasma concentrations of gemcitabine and dFdU over time, as well as its variability in the study population. The accuracy and precision of a posteriori gemcitabine plasma concentrations improved by 67% and 46%, respectively, compared to the a priori prediction.

CONCLUSION

The population pharmacokinetic model adequately characterised the gemcitabine and dFdU plasma concentrations in the study population over time, and can be used to accurately and precisely optimise gemcitabine dosing regimens in cancer patients.

[Populational pharmacokinetics of doxorubicin applied to personalised its dosing in cancer patients]

OBJECTIVE

To develop and internally validate a population pharmacokinetic model for doxorubicin and to evaluate its predictive performance for dose individualization in cancer patients.

METHODS

Doxorubicin plasma concentrations were determined in thirty-three cancer patients treated with intravenous doxorubicin. A three-compartment pharmacokinetic model was implemented in the NONMEN VI programme to determine the doxorubicin pharmacokinetic parameters. The identifiability of the parameters was assessed by parametric bootstrap and model validation was performed using nonparametric bootstrap, visual predictive check, and numerical predictive check. The final model's predictive performance was evaluated in terms of accuracy and precision of plasma concentration predictions during the first and second cycles of chemotherapy.

RESULTS

Doxorubicin clearance was 58.8 L/h, with interpatient variability of 29.2% and intrapatient variability of 18.9%. The estimated volume of distribution at steady state was 2294 L, with inter-and intrapatient variability of 7.3% and 26.1%, respectively. Internal validation confirmed that the population pharmacokinetic model is appropriate to describe the time course of the doxorubicin plasma concentrations and its variability in this population. The accuracy and precision of an a posteriori prediction of doxorubicin plasma concentrations improved by 63% and 41% compared to the a priori prediction.

CONCLUSION

The Bayesian population pharmacokinetic model characterised the time course of doxorubicine plasma concentrations and can be accurately and precisely used to optimise doxorubicine dosing regimens in cancer patients.

Conductivity anisotropy in the antiferromagnetic state of iron pnictides

Recent experiments on iron pnictides have uncovered a large in-plane resistivity anisotropy with a surprising result: The system conducts better in the antiferromagnetic x direction than in the ferromagnetic y direction. We address this problem by calculating the ratio of the Drude weight along the x and y directions, D(x)/D(y), for the mean-field Q=(π,0) magnetic phase diagram of a five-band model for the undoped pnictides. We find that D(x)/D(y) ranges between 0.2<D(x)/D(y)<1.7 for different interaction parameters. Large values of the orbital ordering favor an anisotropy opposite to the one found experimentally. On the other hand, D(x)/D(y) is strongly dependent on the topology and morphology of the reconstructed Fermi surface. Our results point against orbital ordering as the origin of the observed conductivity anisotropy, which may be ascribed to the anisotropy of the Fermi velocity.

Low magnetization and anisotropy in the antiferromagnetic state of undoped iron pnictides

We examine the magnetic phase diagram of iron pnictides using a five-band model. For the intermediate values of the interaction expected to hold in the iron pnictides, we find a metallic low moment state characterized by antiparallel orbital magnetic moments. The anisotropy of the interorbital hopping amplitudes is the key to understanding this low moment state. This state accounts for the small magnetization measured in undoped iron pnictides and leads to the strong exchange anisotropy found in neutron experiments. Orbital ordering is concomitant with magnetism and produces the large zx orbital weight seen at Γ in photoemission experiments.

UGT1A1,A7 and A9 genotyping and pharmacokinetics of irinotecan-containing chemotherapy in patients with advanced cancer

e14563

Background: To the best of our knowledge only one previous report in asian lung cancer patients (pts) assesed UGT1A1, A7 and A9 genotypes along with irinotecan pharmacokinetics (Han et al. JCO 2006; 24: 2237–44). We set out to evaluate UGT1A1, A7 and A9 genotypes in caucasian cancer patients and their relationship with both irinotecan toxicity and irinotecan pharmacokinetics. Methods: UGT1A1, A7 and A9 genotypes were obtained from blood genomic DNA by direct sequencing. The area under the time-concentration curve (AUC) of SN-38 and SN-38G were calculated. The ratio between these AUCs (AUC SN-38G /AUC SN-38) was also calculated. Associations between pharmacokinetics parameters and the UGT1A genotypes were assessed by univariate analysis. Toxicity was collected using standard NCI grading criteria. Statistical correlation between presence of grade III and IV toxicity and UGT1A1,A7 and A9 genotypes was done by Pearson's Chi square. At least 80 patients (with both genotype and pharmacokinetics) are needed to achieve enough statistical power. Results: At the time of writing this abstract, complete genotyping and toxicity data from 59 patients were available. Sex (females 17, males 42). Median age 60 (range 25–88). Pathology (no. pts): lung (26), colon (17), others (16). 21 pts. (35.59%) had received previous chemotherapy. All but 5 pts received doses of irinotecan between 120 and 150 mg/m2. Median no. of cycles 6 (range 1–15). The frequencies of the different UGT1A1, A7 and A9 genotypes are similar to those previously reported. At least one episode of grade III or IV leukopenia was present in 19 pts. (32.2%), and grade III diarrea in 11 pts (18.6%). No statistically significant correlation was found between presence of leukopenia grades III and IV, and the genotypes UGT1A1,A7, and A9 (P=0.687, P=0.156 and P=0.476, respectively). Diarrea grade III was not statistically significantly associated with UGT1A1 (P=0.318), A7 (P=0.318) and A9 (P=0.158). 21 out of 59 pts. had pharmacokinetics (PK) data available. In genotype-PK association analysis, UGT1A1,A7 and A9 were not statistically associated with AUC SN-38G / AUC SN-38 ratios (P=0.844, P=0.911, P=0.431, respectively). Conclusions: Patients are still being accrued to achieve the targeted size.

No significant financial relationships to disclose.

Phenomenological description of the two energy scales in underdoped cuprate superconductors

Raman and angle-resolved photoemission spectroscopy experiments have demonstrated that in superconducting underdoped cuprates nodal and antinodal regions are characterized by two energy scales instead of the one expected in BCS theory. The nodal scale decreases with underdoping while the antinodal one increases. Contrary to the behavior expected for an increasing energy scale, the antinodal Raman intensity decreases with decreasing doping. Using the Yang-Rice-Zhang model, we show that these features are a consequence of the nonconventional nature of the superconducting state in which superconductivity and pseudogap correlations are both present and compete for the phase space.

Modelling intestinal absorption of salbutamol sulphate in rats

The objective was to develop a semiphysiological population pharmacokinetic model that describes the complex salbutamol sulphate absorption in rat small intestine. In situ techniques were used to characterize the salbutamol sulphate absorption at different concentrations (range: 0.15-18 mM). Salbutamol sulphate at concentration of 0.29 mM was administered in presence of verapamil (10 and 20 mM), grapefruit juice and sodium azide (NaN3) (0.3, 3 and 6 mM). Different pharmacokinetic models were fitted to the dataset using NONMEM. Parametric and non-parametric bootstrap analyses were employed as internal model evaluation techniques. The validated model suggested instantaneous equilibrium between salbutamol sulphate concentrations in lumen and enterocyte, and the salbutamol sulphate absorption was best described by a simultaneous passive diffusion (ka = 0.636 h(-1)) and active absorption (VMax = 0.726 mM/h, Km = 0.540 mM) processes from intestinal lumen to enterocyte, together with an active capacity-limited P-gp efflux (V'max = 0.678 mM/h, K'm = 0.357 mM) from enterocyte to intestinal lumen. The extent of salbutamol sulphate absorption in rat small intestine can be improved by NaN3, grapefruit juice and verapamil.

The influence of active secretion processes on intestinal absorption of salbutamol in the rat

Salbutamol was perfused in the small intestine of rat using a standard rat gut "in situ" preparation: (1) in inhibitor-free solution at seven different concentrations (0.15, 0.29, 1.20, 5.0, 9.0, 13.0 and 18.0mM); (2) at a 0.29mM concentration - thought to be close to the allometric dose in man - in the presence of a non-specific enzyme inhibitor, sodium azide (0.3, 3.0 and 6.0mM); and (3) at 0.29mM in the presence of a selective secretion inhibitor, verapamil (10.0 and 20.0mM). In free solution, the mixed-order rate constants, k'(a), of salbutamol increase as the solute concentration increases until an apparent asymptotic value is reached. This could be due to the saturation of enzymatic systems responsible for the secretion of the drug from the enterocyte to the luminal fluid, a process that could explain the poor absorption of salbutamol. In the presence of sodium azide, the k(a) values increased about 1.5-fold, whereas in the presence of verapamil they increased two- to three-fold. These results indicate that salbutamol can act as a substrate of an intestinal secretory transport, which probably includes--at least in part--the enzyme P-glycoprotein, since verapamil has been shown to inhibit this enzyme by dose-dependent competition. This leads to a secretion-limited peroral absorption of salbutamol, which contributes to the poor oral bioavailability of the drug. The possible options for improving salbutamol absorption are discussed.

[Juvenile myoclonic epilepsy. Life difficulties and response to treatment]

Juvenile myoclonic epilepsy (JME) may have different forms of clinical expression and produces different kinds of life difficulties. Both eventualities have not been sufficiently described in the literature. Treatment with valproic acid is useful but requires strict compliance of medical instructions. Thirty two patients with this disease, are presented in order to describe their presenting forms, associated life handicaps and the results of their treatment. The disease may first present as tonic-clonic, complex absence or complex partial seizures, followed months or years later, by typical myoclonic crisis or as JME to which other kinds of epileptic crisis may or not be added after some time. Twenty four (75%) patients had 38 life difficulties, these being, mainly, objects dropped from hand, burns and parental aggression. Eighteen (56.25%) patients had relapses during treatment. In 14 cases (77.77%) relapses were due to noncompliance, 8 (57.19%) patients couldn't afford the cost of valproic acid. Knowledge of the presenting forms of the disease may favor opportune diagnosis and treatment, which would prevent life difficulties. Relapses are mainly due to noncompliance and economic reasons.

[Juvenile myoclonic epilepsy: Janz' syndrome]

Thirty two patients with juvenile myoclonic epilepsy are described. The most relevant aspects of the disease are the following: it starts at nearly 12 years of age or before; it is frequently associated with generalized tonic-clonic seizures; myoclonic and tonic-clonic seizures occur at time of awaking or shortly after; no pathological findings occur at the central nervous system; a large number of relatives show generalized seizures and the interictal electroencephalogram is usually disturbed by generalized epileptic activity. Valproic acid, preferably alone, is probably the treatment of choice for these patients.

[Follow-up of infants with birth weight under 1,500 g]

A prospective study of 199 children with birth weight less than 1,500 g was done. 86 boys and 113 girls, 141 (71%) adequate for gestational age and 58 (29%) small for gestational age. At follow-up 43 (21.6%) infants were lost to control, 17 (7%) moved to other places and 7 (3.5%) died in the first year of life. In the first year of life, infants whose birthweights were adequate for gestational age had been hospitalized more frequently and the small for dates showed higher percentage of undernutrition. After the second year of life, it was possible to know the impairment. It was found 7.4% of cerebral palsy, 2.9% of hipoacusia and 2.2% of retinopathy of prematurity, these diagnosis were most frequent in children that were adequate for gestational age. We concluded that small for dates infants are at risk of undernutrition and that those adequate for gestational age are at risk of permanent sequelae.

The early development of the atrioventricular node and bundle of His in the embryonic chick heart. An electrophysiological and morphological study

The development of the atrioventricular node and bundle of His of embryonic chick hearts was studied by electrophysiological and morphological techniques. The dorsal wall of the AV canal and the interatrial septum were explored to determine if they contribute to the formation of the AV node and bundle of His. The resting membrane and action potentials of the interatrial septum cells were systematically analyzed and found to undergo progressive differentiation with development. The earliest identification of the AV node and upper bundle of His group of cells was achieved at 5 1/2–6 days of development by the electrical recording of their corresponding characteristic action potentials, from a circumscribed area located in the lowest and dorsal segment of the interatrial septum. The morphological and anatomical characterization of the cells was made following electrical recording and labelling with charcoal particles. The earlier AV node and bundle of His responses had similar characteristics to those of the adult heart. It is concluded that the AV node and upper bundle of His cells derive from the low interatrial septum. The possibility that AV canal cells contribute to this event was discarded. The functional relationship of the Av node and bundle of His with other cardiac tissues during the early development of the heart is discussed.

Electrophysiological and ultrastructural study of the atrioventricular canal during the development of the chick embryo

The development of the atrioventricular canal (A-V canal) of embryonic chick hearts (35 to 120 h) was studied by morphological and electrophysiological techniques. The earliest identification of the A-V canal action potentials was at 45 to 49 h of incubation coinciding with the atrium formation and the appearance of its corresponding distinctive action potential. At that time the first atrioventricular delay was recorded and its action potentials showed a low rate of rise, particularly at the initiation of the upstroke and a long duration. The conduction velocity was the lowest in the A-V canal. As the development proceeded from 45 to 120 h, the cardiac cells of the A-V canal showed scanty membrane to membrane contacts and large intercellular spaces filled with abundant extracellular matrix components, in striking contrast to the paucity of these components in the atrium and ventricle. The morphological and electrophysiological characteristics described for the A-V canal cells, could help to explain their slow conduction properties and the atrioventricular delay.